|Bid||34.41 x 1000|
|Ask||37.65 x 900|
|Day's Range||33.46 - 36.20|
|52 Week Range||30.05 - 61.25|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||17.60|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.75|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Supernus Pharmaceuticals...
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SUPN are favorable, with net inflows of $2.49 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
ROCKVILLE, Md., April 01, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders might be concerned after seeing the share price drop 15% in...
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) reported Thursday mixed results from a phase 3 clinical trial for its attention deficit hyperactivity disorder treatment — and investors were not pleased. The Rockville company, which focuses on products for central nervous system diseases, failed to demonstrate that a 600-milligram dose of its drug candidate, called viloxazine hydrochloride, could effectively reduce ADHD symptoms in adolescents. The stock dipped Thursday as much as 4 percent to $32.90 per share before crawling up to $34.18, a 0.58 percent drop from Wednesday's closing price, by 3 p.m. But Supernus President and CEO Jack Khattar said this latest outcome won't stop the company from advancing the product to market, according to remarks he made on a conference call about the results.
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced topline results from the second Phase III study of SPN-812 in adolescents (P304) for the treatment of attention deficit hyperactivity disorder (ADHD).
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Thursday, March 28, 2019, at approximately 8:00 a.m. ET, it will issue a press release announcing the results of its final Phase III study for SPN-812 in patients 12-17 years old (P304) for the treatment of attention deficit hyperactivity disorder (ADHD). The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy.
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), with a market cap of US$2.0b, are often out of theRead More...
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ROCKVILLE, Md., March 06, 2019 -- Supernus Pharmaceuticals, Inc. (NASADQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Warning! GuruFocus has detected 5 Warning Sign with G. Click here to check it out.
Chevy Chase venture capital juggernaut New Enterprise Associates Inc. is raising a new fund with a ceiling of $3.6 billion, according to a Securities and Exchange Commission filing made Friday. New Enterprise Associates 16, which the company raised in 2017, was $3.5 billion, according to PitchBook. NEA has increased its fund size each time since its first $16 million fund in 1978.
Supernus Pharmaceuticals (SUPN) potentially offers a rare combination of traditional value, backed by sales of its approved drugs, and upside excitement thanks to its high-potential pipeline assets, asserts growth stock expert Doug Gerlach, editor of Investor Advisory Service.
NEW YORK, NY / ACCESSWIRE / February 27, 2019 / Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 27, ...
Fourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2017.Fourth.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
ROCKVILLE, Md., Feb. 12, 2019 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
Want to participate in a short research study? Help shape the future of investing tools and receive a $60 prize! I am going to run you through how I calculated Read More...